$阿斯利康 (AZN.US)$AdCom for IMFINZI (durvalumab) tomorrow 7/25 🗓️
» IMFINZI + platinum-containing chemo
» as Tx for non-small cell lung cancer (NSCLC)
Briefing docs for Thursday’s AdCom posted yesterday…
⚠️ FDA highlights concerns about Imfinzi for perioperative NSCLC:
» overtreatment risk
» uncertainty on treatment benefit
» inadequate trial design
» lack of overall survival benefit
» potential for unnecessary exposure
⏰ Meeting begins Thursday, 9 a.m. ET.
Green Dragon 2024 : 这完全有道理。特别是,当汤姆·李表示小盘股应该增长40%时(罗素)。很棒的信息谢谢!